Robert Davis, MD
Internal Medicine · Corvallis, ORNPI 1629481452
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,056 of the $5,743 with a category attached, or 88.0%. It is spread thinly across 59 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$777
- Astellas Pharma US Inc$534
- E.r. Squibb & Sons, L.L.C.$301
- Janssen Scientific Affairs, LLC$285
- Gilead$271
- Tempus AI, Inc$262
- plus $3K from 53 others
Across 7 payments — averaging $22,729 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$159K
What the payments were for
- Food & beverage$5,05688%
- Education$68712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,743 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 24 | $467,517 |
| Lenalidomide | 31 | $394,931 |
| IbrancePalbociclib | 16 | $263,390 |
| RevlimidLenalidomide | 14 | $245,366 |
| ImbruvicaIbrutinib | 13 | $187,559 |
| VerzenioAbemaciclib | 12 | $184,037 |
| VenclextaVenetoclax | 19 | $183,599 |
| CalquenceAcalabrutinib Maleate | 21 | $163,016 |
| ErleadaApalutamide | 12 | $158,265 |
| EliquisApixaban | 104 | $108,872 |
| Abiraterone Acetate | 71 | $63,617 |
| OrgovyxRelugolix | 16 | $41,825 |
| OxycontinOxycodone Hcl | 13 | $16,029 |
| Letrozole | 124 | $4,300 |
| Tamoxifen Citrate | 115 | $3,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $21 | $467,51724 claims |
| PfizerIbrance, Eliquis | $233 | $372,262120 claims |
| Bristol Myers SquibbRevlimid | $46 | $245,36614 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $16 | $187,55913 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $159 | $184,31538 claims |
| AbbVieVenclexta | $108 | $183,59919 claims |
| AstraZenecaCalquence | $777 | $163,01621 claims |
| Johnson & JohnsonErleada | $200 | $158,26512 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $285 | $63,61771 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $29 | $41,82516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Corvallis
- Robin McKelveyCorvallis$18K
- Tomer PellegCorvallis$2K
- Chad PfeferBeaverton$639K
- Pranav ChandrashekarPortland$81K
- Jonathan EdmistonBend$68K
- Jessica CastlePortland$66K
- Ellen Schiaffino PurvisGresham$66K
- Steven ShawWhite City$58K
- Stephen SpurgeonPortland$42K
- Jane BabiarzPortland$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.